IFNA1 and arthritic joint disease: The increased IFN activity in the preclinical phase of RA was confirmed in pre-onset RA patients (samples from the Medical Biobank of Northern Sweden).70 The combined analysis of such IFN and B-cell signature in an independent validation cohort of seropositive arthralgia patients confirmed a significant high risk for arthritis development in IFN-high/B-cell-low profile (80%, odds ratio 6.22) and a low risk for IFN-low/B-cell-high profile (26%, odds ratio 0.16).